GBA1 and early-onset autosomal dominant Alzheimer disease: Furthermore, its favorable safety profile combined with its cognitive memory-enhancing effects [76] and its demonstrated efficacy in models of neurodegenerative disease, such as prion disease [113] and Alzheimer’s disease [114], make it an attractive therapeutic candidate for GBA1-PD.